Comparative effectiveness of antihypertensive therapeutic classes and treatment strategies in the initiation of therapy in primary care patients: a Distributed Ambulatory Research in Therapeutics Network (DARTNet) study

Michael R Bronsert, William G Henderson, Robert Valuck, Patrick Hosokawa, Karl Hammermeister, Michael R Bronsert, William G Henderson, Robert Valuck, Patrick Hosokawa, Karl Hammermeister

Abstract

Background: Few comparative effectiveness studies of treatment strategies using antihypertensive therapeutic classes in hypertension control have been assessed in a primary care environment. The objectives are to compare the effectiveness of common antihypertensive therapeutic classes initiated as monotherapy and of fixed-dose combinations (FDCs), free-equivalent combinations (FECs), and monotherapy on hypertension control.

Methods: This article reports observational comparative effectiveness analyses of data electronically extracted from electronic health records. The study population consisted of 8,676 patients with an incident prescription for an antihypertensive agent of a total of 79,176 patients receiving antihypertensive therapy in 33 geographically diverse primary care clinics. The main measures were reductions in systolic blood pressure (SBP) and diastolic blood pressure (DBP) and rates of attaining goals per the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7).

Results: There were small, clinically insignificant differences in blood pressure reductions between the monotherapy classes. Higher rates of blood pressure control were obtained when patients were initiated on an angiotensin-converting enzyme inhibitor than a thiazide or thiazide-like diuretic (47.8% vs 39.9%) or a β-blocker versus a thiazide (45.9% vs 39.9%). Patients initiated on FDCs had significantly larger reductions in blood pressure than patients initiated on FECs (-17.3 vs -12.0 mm Hg SBP; -10.1 vs -6.0 mm Hg DBP) or monotherapy (-17.3 vs -13.6 mm Hg SBP; -10.1 vs -7.9 mm Hg DBP). Rates of attaining JNC7 goals also were better for FDCs than FECs (57.2% vs 42.5%) and for FDCs versus monotherapy (57.2% vs 44.9%).

Conclusions: Patients initiated on angiotensin-converting enzyme inhibitors and β-blockers had slightly higher rates of blood pressure control. The use of FDCs as initial therapy is more effective in the control of hypertension than monotherapy or FECs.

Keywords: Antihypertensives; Comparative Effectiveness Research; Drug Therapy; Hypertension; Practice-based Research; Primary Health Care.

Conflict of interest statement

The authors have no conflicting or competing interests.

Figures

Figure 1
Figure 1
Time-line defining key events in study: for initial use antihypertensive (anti-HTN) patients.
Figure 2
Figure 2
STROBE diagram of initial use antihypertensive (anti-HTN) patient inclusion.

References

    1. Roger VL, Go AS, Lloyd-Jones DM, et al. Executive Summary: Heart Disease and Stroke Statistics-2012 Update: A Report from the American Heart Association. Circulation. 2012;125:188–197.
    1. Lewington S, Clarke R, Qizibash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies: prospective studies collaboration. Lancet. 202;360:1903–1913.
    1. Collins R, Peto R, MachMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827–838.
    1. Turnbull F. Blood Pressure Lowering Treatment Trialists’ Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet. 2003;362:1527–1535.
    1. Chobanian AV, Bakris GL, Black HR, et al. the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–1252.
    1. Cushman WC, Ford CE, Cutler JA, et al. ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) J Clin Hypertens (Greenwich) 2002;4:393–404.
    1. Bakris GL, Weir MR on behalf of the study of hypertension and the efficacy of Lotrel in diabetes (SHIELD) investigators. Achieving goal blood pressure in patients with type 2 diabetes: Conventional versus fixed-dose combination approaches. J Clin Hypertens. 2003;5(3):202–209.
    1. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker Amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet. 2011;377:312–320.
    1. Neutel JM, Mancia G, Black HR, et al. behalf of the TEAMSTA severe HTN study investigators. Single-pill combination of Telmisartan/Amlodipine in patients with severe hypertension: Results from the TEAMSTA severe HTN study. J Clin Hypertens. 2012;14(4):206–215.
    1. Baser O, Andrews LM, Wang L, Xie L. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated Valsartan/Amlodipine singe-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy. J Med Econ. 2011;14(5):576–583.
    1. Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs. free-equivalent combination therapies for hypertension: A meta-analysis of health care costs and adherence. J Clin Hypertens. 2011;13(12):898–909.
    1. Libby AM, Pace W, Bryan C, et al. Comparative effectiveness research in DARTNet primary care practices: point of care data collection on hypoglycemia and over-the -counter and herbal use among patients diagnosed with diabetes. Med Care. 2010;48(6):S39–S44.
    1. Pace WD, Cifuentes M, Valuck RJ, Staton EW, Brandt EC, West DR. An electronic practice-based network for observational comparative effectiveness research. Ann Intern Med. 2009;151(5):338–340.
    1. Pace WD, West DR, Valuck RJ, Cifuentes M, Staton EW. Distributed Ambulatory Research in Therapeutics Network (DARTNet): Summary Report. Rockville, MD: Agency for Healthcare Research and Quality; 2009. Jul 28, (Prepared by University of Colorado DEcIDE Center under Contract No. HHSA29020050037I TO2.) Report No.: 14.
    1. Levely AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604–12.
    1. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427.
    1. Neaton JD, Grimm RH, Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. JAMA. 1993;270(6):713–724.
    1. Cushman WC, Ford CE, Einhorn PT, et al. ALLHAT Collaborative Research Group. Blood pressure control by drug group in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) J Clin Hypertens (Greenwich) 2008;10(10):751–760.
    1. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. N engl J Med. 1993;328:914–921.
    1. Byrd JB, Zeng C, Tavel HM, et al. Combination therapy as initial treatment for newly diagnosed hypertension. Am Heart J. 2011;162:340–346.
    1. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenber KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59:1124–1131.
    1. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4:42–50.
    1. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:243–262.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren